Rapidly dissolvable microneedle patches for transdermal delivery of exenatide

Pharmaceutical Research

Volumn 31, Issue 12, 2014, Pages 3348-3360

  Zhu, Zhuangzhi ^a   Luo, Huafei ^a   Lu, Wangding ^a   Luan, Hansen ^a   Wu, Yubo ^a   Luo, Jing ^a   Wang, Youjie ^b   Pi, Jiaxin ^a   Lim, Chee Yen ^c   Wang, Hao ^a  

^a National Pharmaceutical Engineering Research Center   (China)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c Micropoint Technologies Pte Ltd   (Singapore)

Author keywords

dissolving microneedles; exenatide; pharmacokinetics pharmacodynamics; transdermal delivery; type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; EXENDIN 4; HYALURONIC ACID; PEPTIDE; VENOM;

ANIMAL; BLOOD; DRUG STABILITY; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; MALE; NEEDLE; RAT; SPRAGUE DAWLEY RAT; THERMOREGULATION; TRANSDERMAL PATCH;

ANIMALS; DRUG STABILITY; GLUCOSE TOLERANCE TEST; HYALURONIC ACID; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; NEEDLES; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; TRANSDERMAL PATCH; VENOMS; WATER LOSS, INSENSIBLE;

EID: 84936131175     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1424-1     Document Type: Article

References (39)

1. DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773-95.
2. Association AD. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2008;31(Supplement 1):S55-S60.
3. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem. 1992;267(11):7402-5.
4. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Peptides. 2004;117(2):77-88.
5. Cai Y, Wei L, Ma L, Huang X, Tao A, Liu Z, et al. Long-acting preparations of exenatide. Drug Des Dev Ther. 2013;7:963-70.
6. Gedulin BR, Smith PA, Jodka CM, Chen K, Bhavsar S, Nielsen LL, et al. Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration. Int J Pharm. 2008;356(1-2):231-8.
7. Ahn S, Lee I-H, Lee E, Kim H, Kim Y-C, Jon S. Oral delivery of an anti-diabetic peptide drug via conjugation and complexation with low molecular weight chitosan. J Control Release. 2013;170(2):226-32.
8. Nguyen H-N, Wey S-P, Juang J-H, Sonaje K, Ho Y-C, Chuang E-Y, et al. The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo. Biomaterials. 2011;32(10):2673-82.
9. Lee J, Lee C, Kim TH, Lee ES, Shin BS, Chi S-C, et al. Self-assembled glycol chitosan nanogels containing palmityl-acylated exendin-4 peptide as a long-acting anti-diabetic inhalation system. J Control Release. 2012;161(3):728-34.
10. Lee C, Choi JS, Kim I, Oh KT, Lee ES, Park ES, et al. Long-acting inhalable chitosan-coated poly(lactic-co-glycolic acid) nanoparticles containing hydrophobically modified exendin-4 for treating type 2 diabetes. Int J Nanomed. 2013;8:2975-83.
11. Hamman J, Enslin G, Kotzé A. Oral delivery of peptide drugs. BioDrugs. 2005;19(3):165-77.
12. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261-8.
13. Hiraishi Y, Nakagawa T, Quan Y-S, Kamiyama F, Hirobe S, Okada N, et al. Performance and characteristics evaluation of a sodium hyaluronate-based microneedle patch for a transcutaneous drug delivery system. Int J Pharm. 2013;441(1-2):570-9.
14. Arora A, Prausnitz MR, Mitragotri S. Micro-scale devices for transdermal drug delivery. Int J Pharm. 2008;364(2):227-36.
15. Gill HS, Denson DD, Burris BA, Prausnitz MR. Effect of microneedle design on pain in human volunteers. Clin J Pain. 2008;24(7):585-94.
16. Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev. 2012;64(14):1547-68.
17. Van der Maaden K, Jiskoot W, Bouwstra J. Microneedle technologies for (trans) dermal drug and vaccine delivery. J Control Release. 2012;161(2):645-55.
18. Lee JW, Park JH, Prausnitz MR. Dissolving microneedles for transdermal drug delivery. Biomaterials. 2008;29(13):2113-24.
19. Migalska K, Morrow DI, Garland MJ, Thakur R, Woolfson AD, Donnelly RF. Laser-engineered dissolving microneedle arrays for transdermal macromolecular drug delivery. Pharm Res. 2011;28(8):1919-30.
20. Kolli CS, Banga AK. Characterization of solid maltose microneedles and their use for transdermal delivery. Pharm Res. 2008;25(1):104-13.
21. Martin CJ, Allender CJ, Brain KR, Morrissey A, Birchall JC. Low temperature fabrication of biodegradable sugar glass microneedles for transdermal drug delivery applications. J Control Release. 2012;158(1):93-101.
22. Lee JW, Choi SO, Felner EI, Prausnitz MR. Dissolving microneedle patch for transdermal delivery of human growth hormone. Small. 2011;7(4):531-9.
23. Sullivan SP, Koutsonanos DG, Del Pilar MM, Lee JW, Zarnitsyn V, Choi SO, et al. Dissolving polymer microneedle patches for influenza vaccination. Nat Med. 2010;16(8):915-20.
24. Ito Y, Hirono M, Fukushima K, Sugioka N, Takada K. Two-layered dissolving microneedles formulated with intermediate-acting insulin. Int J Pharm. 2012;436(1-2):387-93.
25. Liu S, Jin MN, Quan YS, Kamiyama F, Katsumi H, Sakane T, et al. The development and characteristics of novel microneedle arrays fabricated from hyaluronic acid, and their application in the transdermal delivery of insulin. J Control Release. 2012;161(3):933-41.
26. Matsuo K, Yokota Y, Zhai Y, Quan Y-S, Kamiyama F, Mukai Y, et al. A low-invasive and effective transcutaneous immunization system using a novel dissolving microneedle array for soluble and particulate antigens. J Control Release. 2012;161(1):10-7.
27. Hirobe S, Azukizawa H, Matsuo K, Zhai Y, Quan Y-S, Kamiyama F, et al. Development and clinical study of a self-dissolving microneedle patch for transcutaneous immunization device. Pharm Res. 2013;30(10):2664-74.
28. Liu S, Jin M-n, Quan Y-s, Kamiyama F, Kusamori K, Katsumi H, et al. Transdermal delivery of relatively high molecular weight drugs using novel self-dissolving microneedle arrays fabricated from hyaluronic acid and their characteristics and safety after application to the skin. Eur J Pharm Biopharm. 2014;86(2):267-76.
29. Fraser JRE, Laurent TC, Laurent UBG. Hyaluronan: its nature, distribution, functions and turnover. J Intern Med. 1997;242(1):27-33.
30. Cohen JL, Dayan SH, Brandt FS, Nelson DB, Axford-Gatley RA, Theisen MJ, et al. Systematic review of clinical trials of small- and large-gel-particle hyaluronic acid injectable fillers for aesthetic soft tissue augmentation. Dermatol Surg. 2013;39(2):205-31.
31. Greenspan L. Humidity fixed points of binary saturated aqueous solutions. J Res Nat Bur Stand. 1977;81(1):89-96.
32. Ling M-H, Chen M-C. Dissolving polymer microneedle patches for rapid and efficient transdermal delivery of insulin to diabetic rats. Acta Biomater. 2013;9(11):8952-61.
33. Kehler JR, Bowen CL, Boram SL, Evans CA. Application of DBS for quantitative assessment of the peptide Exendin-4; comparison of plasma and DBS method by UHPLC-MS/MS. Bioanalysis. 2010;2(8):1461-8.
34. Chae SY, Choi YG, Son S, Jung SY, Lee DS, Lee KC. The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics. J Control Release. 2010;144(1):10-6.
35. Chen M-C, Ling M-H, Lai K-Y, Pramudityo E. Chitosan microneedle patches for sustained transdermal delivery of macromolecules. Biomacromolecules. 2012;13(12):4022-31.
36. Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care. 1997;20(12):1822-6.
37. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372(9645):1240-50.
38. Yu L, Li K, Liu X, Chen C, Bao Y, Ci T, et al. In vitro and in vivo evaluation of a once-weekly formulation of an antidiabetic peptide drug exenatide in an injectable thermogel. J Pharm Sci. 2013;102(11):4140-9.
39. Gill HS, Prausnitz MR. Coated microneedles for transdermal delivery. J Control Release. 2007;117(2):227-37.